Chinese
Japan
English
Innovation & Quality Series
Join our expert webinars on Biologics
ProBio is committed to proactively providing professional solutions and controllable processes from drug discovery through commercialization to accelerate drug development for our customers. To learn more, please join our expert webinar series on biologics.
Feb. 27th11:00-11:40 am EST
Dr. Li Chen, Senior Project Manager, ProBio
An idiotype can be defined as the specific combination of idiotopes present within an antibody complementarity-determining regions. Since anti-ID Abs are capable of binding to antibody drugs within biological fluids, they are commonly used in a preclinical setting for antibody drug pharmacokinetics (PK) and pharmacodynamics (PD). In this webinar, we will introduce anti-idiotype antibody application and generation, and share a case study.
Mar. 13th11:00-11:40 am EST
Dr. Manzhu Kang, Senior Scientist, ProBio
In this webinar we introduce single cell technology in immunology and antibody screening, including its emergence, various approaches, benefits, and the current state of its industrial applications. We summarize the advantages of single B cell screening and discuss how to maximize your antibody screening success when selecting various technologies, by comparing different platforms, from hybridoma, to single B cell screening, to library display.
Apr. 3rd11:00-11:40 am EST
Dr. Yikai Qiu, Senior Scientist, ProBio
Antibodies have emerged as significant therapeutics in the market. Accelerating antibody discovery is essential in the fight to develop first-in-class drugs or treatments for new pandemic pathogens, such as coronavirus. Fully human antibody discovery is widely used in early antibody leads discovery. In this webinar, we compare how scientists use innate immune systems to develop phage displayed libraries, Ab humanized animals, and single B cell technology. Recommended strategies for human antibody discovery will also be discussed.
Apr. 15th11:00-11:40 am EST
In this webinar we introduce therapeutic antibodies, focusing on the opportunities and challenges of current monotherapy. We analyze the major benefits of bispecific antibodies and the current formats used in clinical trails. Additionally, we share an in-depth, integrated SMAB (single-domain antibody fused to monoclonal antibody) case study from rational design to preclinical development.
Mar. 18th11:00-11:40 am EST
Dr. Sean Liour, Head of PM & RA, ProBio
In this webinar we introduce key technologies in cell line development and discuss how to achieve desired cell lines. We also share several cell line development case studies from GenScript.